Travere Therapeutics (NASDAQ: TVTX) price objective was lowered by H.C. Wainwright analyst Ed Arce to $42.00 from $46.00, maintaining a buy rating.
On May 5, 2022, Teva Therapeutics (NASDAQ: TVTX) announced first-quarter earnings of ($0.82), beating the consensus expectation of ($0.85) by one cent. They earned $48.5 million compared to their forecast of $51.92 million, which was better than expected. $603.4 million was held in cash, cash equivalents, and marketable securities as of December 31. March 2022.
As of January 10, 2022, Travere Therapeutics (NASDAQ: TVTX) has forecast net product sales of $55 million for the fourth quarter of 2021, based on preliminary, unaudited financial data. According to the company’s estimates, about $211 million in net product sales and $16 million in license and partnership revenue are expected for fiscal 2021. It also included an overview of the company’s plans for the future, including projected milestones for the year 2022.
“We enter 2022 with great confidence in our ability to deliver life-changing new therapies to people living with rare diseases,” said Eric Dube, Ph.D., executive director of Travere Therapeutics, “after three positive reads from our pipeline. and continued strong execution of our commercial business over the past year.”
If authorized, sparsentan could provide a new standard of care for patients with uncommon kidney disorders such as IgA nephropathy and FSGS.” With our NDA and MAA filings planned, we are slated for the first IgA nephropathy approvals in the US until the end of this year. A crucial pegtibatinase program is now in place to engage with regulators and develop the next steps for a drug that can be used to treat the underlying deficit in classical homocystinuria,” according to the study’s lead author.
Biopharmaceutical business Travere Therapeutics is developing and commercializing therapeutic products for treating metabolic illnesses such as type 2 diabetes. Based in New York City, New York, the firm has been around since 2014. First-of-its-kind, extended-release, oral diabetic medication Traverextend is the company’s primary product candidate. As an injectable-free, once-daily treatment for people with both type 1 and type 2 diabetes, Traverextend has been examined extensively.